Vaxxas secures funding for clinical trials of nanopatch delivered vaccines

update: WHO says tech like Nanopatch can help get vaccines to the people that need them

Vaxxas raises $20m for nanopatch vaccine trials

By Gareth Macdonald

Vaccine patch firm Vaxxas has raised $20m (€17.7m) to fund clinical development of its pipeline of influenza, polio and bacterial infection vaccines.

GSK is preparing 10,000 doses as a Phase I trial begins.

GSK begins manufacturing 10,000 Ebola vaccine doses for WHO

By Zachary Brennan

As more than half a dozen companies are now vying to help treat and vaccinate Ebola victims in West Africa, where nearly 3,000 people have died from the illness, GlaxoSmithKline is taking the lead in getting product manufactured.

Snip, snip: CRISPR-Cas allows scientists to cut out (and insert) genes.

Patents and profits: the battle to own CRISPR

By Fiona BARRY

CRISPR, the gene-editing technology that could revolutionise biologics, is set to become a patent battleground as companies vie over who owns the tool and its products, says an intellectual property expert.

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

By Zachary Brennan

Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer. 

Pfizer eyes Parkinson’s disease treatments with MedGenesis pact

Pfizer eyes Parkinson’s disease treatments with MedGenesis pact

By Zachary Brennan

Biotech company MedGenesis Therapeutix has granted Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments...

Pfenex set for new direction as it uses its expression technology to develop its biosimilar pipeline

Pfenex focuses on biosimilars post IPO

By Dan Stanton

Revenues from protein production will decline as Pfenex shifts attention to its biosimilar pipeline, the newly public company says.